Improving early detection of high-risk pancreatic cysts
Official title: Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
Funded at Duke University · NIH-11095975 · Data updated 2026-11-12
This research aims to find better ways to tell which pancreatic cysts are likely to become cancer, helping doctors decide who needs treatment sooner.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | September 1, 2014 |
| Project end | June 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $406,824 |
| NIH project number | 5R01CA182076-08 |
| Project ID | NIH-11095975 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for future related studies would be patients diagnosed with intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
✕Less likely to help
Patients without IPMN or those with already advanced, invasive pancreatic cancer may not directly benefit from this specific diagnostic research.
What this research studies
Pancreatic cysts called IPMN are a chance to stop pancreatic cancer before it starts, but it's hard to know which ones are dangerous. Current tests can't reliably tell the difference between low-risk cysts and those that are likely to turn into aggressive cancer. This project uses a new technology called spatial transcriptomics to look closely at tissue from patients with IPMN. By identifying specific markers in these tissues, we hope to develop more accurate diagnostic tools.
Why it matters
Potential benefit: If successful, this work could lead to more accurate tests for pancreatic cysts, allowing for earlier and more precise interventions to prevent pancreatic cancer.
How similar studies have gone: This project utilizes a novel spatial transcriptomics platform to identify specific markers, representing a new approach to distinguish between different types and grades of IPMN.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Allen, Peter J — Duke University
- Study coordinator: Allen, Peter J
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.